Bank of New York Mellon Corp Has $181.12 Million Stock Holdings in Astrazeneca Plc $AZN

Bank of New York Mellon Corp grew its holdings in Astrazeneca Plc (NYSE:AZN) by 2.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,032,000 shares of the company’s stock after purchasing an additional 25,833 shares during the quarter. Bank of New York Mellon Corp’s holdings in Astrazeneca were worth $181,116,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Triumph Capital Management acquired a new position in Astrazeneca during the 3rd quarter worth approximately $25,000. Bangor Savings Bank raised its stake in Astrazeneca by 102.7% during the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after buying an additional 154 shares during the period. Eagle Bay Advisors LLC acquired a new position in Astrazeneca during the 4th quarter worth approximately $30,000. YANKCOM Partnership acquired a new position in Astrazeneca during the 4th quarter worth approximately $31,000. Finally, TFC Financial Management Inc. raised its stake in Astrazeneca by 3,350.0% during the 4th quarter. TFC Financial Management Inc. now owns 345 shares of the company’s stock worth $32,000 after buying an additional 335 shares during the period. 20.35% of the stock is owned by institutional investors and hedge funds.

Astrazeneca Stock Up 2.3%

Shares of NYSE:AZN opened at $186.06 on Friday. The stock’s 50-day moving average price is $190.84 and its 200-day moving average price is $184.91. Astrazeneca Plc has a 12-month low of $137.23 and a 12-month high of $212.71. The stock has a market capitalization of $288.57 billion, a P/E ratio of 27.94, a price-to-earnings-growth ratio of 1.56 and a beta of 0.25. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52.

Astrazeneca (NYSE:AZN) last posted its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The company had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. On average, equities analysts anticipate that Astrazeneca Plc will post 9.52 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have commented on AZN. Morgan Stanley reissued an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a report on Thursday, May 21st. JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. Weiss Ratings began coverage on Astrazeneca in a report on Wednesday, March 11th. They set a “buy (b)” rating for the company. Finally, UBS Group reissued a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.